home / stock / ymtx / ymtx news

YMTX News and Press, Yumanity Therapeutics Inc. From 03/21/22

Stock Information
Company Name: Yumanity Therapeutics Inc.
Stock Symbol: YMTX
Market: NASDAQ
Menu
YMTX YMTX Quote YMTX Short YMTX News YMTX Articles YMTX Message Board
Get YMTX Alerts

News, Short Squeeze, Breakout and More Instantly...
YMTX - YMTX, YQ and VLON among mid-day movers

Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...
YMTX - NeuroSense Therapeutics leads healthcare gainers; Vallon Pharmaceuticals, ImmunoGen among losers

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

YMTX - PAGS, BEKE and ARDX among pre market gainers

StoneCo (STNE) +29% on Q4 results. Kidpik (PIK) +22%. Sunshine Biopharma (SBFM) +16%. Yumanity Therapeutics (YMTX) +12%. On Holding (ONON) +9% on Q4 results. Hycroft Mining Holding (HYMC) +9%. PagSeguro Digital (PAGS) +8%. Houston American Energy (HUSA) +8%. Zhihu (ZH) +8%...

YMTX - Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
YMTX - Yumanity to cut 60% of workforce as it evaluates strategic alternatives for business

Yumanity Therapeutics (NASDAQ:YMTX) has added ~2% in the pre-market on Thursday after the company announced plans to reduce nearly 60% of its workforce by April as part of a strategic restructuring of its business. In addition, Yumanity (YMTX) announced it is evaluating strategic al...

YMTX - Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that it is exploring strategic a...

YMTX - BioCardia, Biophytis top healthcare gainers; Kiromic, Mainz Biomed among losers

Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
YMTX - Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today announced that, in response to its IND app...

YMTX - Yumanity's Approach to Neurodegenerative Diseases Validated by Two External Collaborations

Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation awards grant to accelerate early proof-of-concept testing of promising Parkinson’s disease therapy BOSTON, Jan. 11, 2022 ...

YMTX - Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., Pr...
Previous 10 Next 10